Cooper Companies (NASDAQ:COO) Price Target Lowered to $58.00 at JPMorgan Chase & Co.

Cooper Companies (NASDAQ:COO) had its price objective lowered by analysts at JPMorgan Chase & Co. from $71.00 to $58.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical device company’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 5.66% from the stock’s current price.

A number of other equities analysts have also recently commented on the company. UBS Group reduced their price target on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating for the company in a report on Thursday. Piper Sandler downgraded Cooper Companies from an “overweight” rating to a “neutral” rating and set a $59.00 target price for the company. in a research note on Thursday. Needham & Company LLC decreased their target price on Cooper Companies from $86.00 to $73.00 and set a “buy” rating on the stock in a report on Thursday. The Goldman Sachs Group set a $61.00 price objective on shares of Cooper Companies in a report on Wednesday, May 27th. Finally, Stifel Nicolaus set a $70.00 price objective on shares of Cooper Companies in a research report on Thursday. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $73.47.

Cooper Companies Stock Down 13.5%

COO traded down $8.59 during trading on Thursday, reaching $54.89. 6,560,720 shares of the stock were exchanged, compared to its average volume of 2,372,654. The stock has a market cap of $10.71 billion, a P/E ratio of 46.70, a price-to-earnings-growth ratio of 1.77 and a beta of 0.82. Cooper Companies has a twelve month low of $51.01 and a twelve month high of $89.83. The stock’s 50 day moving average price is $72.42 and its two-hundred day moving average price is $70.02. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter last year, the company posted $0.49 earnings per share. The company’s revenue for the quarter was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities analysts expect that Cooper Companies will post 4.63 EPS for the current year.

Cooper Companies announced that its board has authorized a share repurchase plan on Wednesday, September 9th that allows the company to repurchase $3.00 billion in shares. This repurchase authorization allows the medical device company to purchase up to 22.7% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Institutional Investors Weigh In On Cooper Companies

A number of large investors have recently added to or reduced their stakes in COO. Algert Global LLC bought a new position in Cooper Companies during the second quarter worth $7,655,000. BlackRock Inc. bought a new stake in Cooper Companies during the second quarter valued at $1,077,762,000. Heartland Advisors Inc. bought a new stake in Cooper Companies during the fourth quarter valued at $15,348,000. Tocqueville Asset Management L.P. bought a new position in shares of Cooper Companies in the 2nd quarter worth about $1,502,000. Finally, Western Standard LLC bought a new position in shares of Cooper Companies in the 2nd quarter worth about $5,228,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: COO reported fiscal Q3 adjusted EPS of $1.15, above the $1.11-$1.12 analyst consensus. GAAP EPS was $2.24, helped by a $307.2 million benefit from the favorable completion of a U.K. tax examination. Free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded the share-repurchase authorization from $2 billion to $3 billion, potentially allowing repurchases of up to 22.7% of outstanding shares. Management also said it remains open to strategic alternatives that could create shareholder value. CooperCompanies Completes Strategic Review
• Neutral Sentiment: Third-quarter revenue rose roughly 1% year over year to $1.066 billion, with CooperVision revenue flat at $717 million and CooperSurgical revenue up 2% to $349.2 million. The results show continued profitability but limited underlying growth.
• Negative Sentiment: Revenue missed the approximately $1.10 billion consensus estimate, while fiscal 2026 adjusted EPS guidance was cut to $4.51-$4.55 from expectations near $4.63. Fourth-quarter EPS guidance of $1.05-$1.09 also trails the roughly $1.20 consensus. Analysts Lower Forecasts Following Q3 Results
• Negative Sentiment: CooperCompanies ended its strategic review by retaining CooperSurgical because potential offers were not attractive enough. Investors appear disappointed that the company will not receive sale proceeds, amid valuation pressure from a new non-hormonal IUD competitor and recent fertility-litigation costs.
• Negative Sentiment: Analysts responded by lowering price targets, including Needham to $73 from $86 and Bank of America to $65 from $80. Bank of America maintained a neutral rating, while the forecast reductions reinforced concerns about near-term growth.

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.